# Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

> **NCT00049374** · PHASE2 · COMPLETED · sponsor: **University of Maryland, Baltimore**

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** oblimersen sodium
- **DRUG:** dexamethasone
- **DRUG:** thalidomide

## Key facts

- **NCT ID:** NCT00049374
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2006-01
- **Final completion:** 2006-01
- **Target enrollment:** — (—)
- **Last updated:** 2019-10-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00049374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00049374, "Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00049374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*